TriNetX

TriNetX

TriNetX was founded in 2013 on the premise that better access to real-world data could accelerate medical research. The company operates as a for-profit corporation headquartered in Cambridge, Massachusetts, with offices across the Americas, Europe, and Asia. It does not manage outside capital and operates without a publicly disclosed ownership structure. The firm’s core product is a federated network of electronic health record, claims, lab, and genomic data sourced directly from academic hospital partners — it does not purchase or scrape datasets. Researchers use the network to identify clinical trial sites, design protocols, and generate real-world evidence to support regulatory submissions and health technology assessments. TriNetX’s AI and analytics layer fuses machine learning with oversight from scientists among the top 2% most-cited globally. The platform carries a clinical trial innovation award from the MedTech Breakthrough program (per MedTech Breakthrough Awards, 2026). TriNetX does not disclose revenue, funding rounds, or investor names. The firm declines to report the number of employees. The company’s secure network spans 13,000+ clinical sites across 20+ countries and has supported thousands of peer-reviewed publications. In 2024 it issued a UK Modern Slavery Act statement, signaling ongoing operational compliance. A structural differentiator is TriNetX’s federated architecture: patient data never leaves the originating health system. This model preserves privacy, provenance, and granularity while enabling global queries — a design choice that sets the network apart from aggregated data vendors and allows direct source validation.